Morepen Laboratories Limited — Updates, 13-05-2025: Press Release

Morepen Laboratories has announced a board meeting on finalizing the financial results for the quarter and half-year. FY25 performance shows 7.4% revenue growth to ₹1,830 crore, EBITDA up 21.6% to ₹118 crore, and PAT at ₹118 crore. EPS rose 17% to ₹2.20. The API segment leads with ₹989 crore, boosted by exports to 80+ countries, while Medical Devices grew 12% to ₹496 crore. The company plans to declare a dividend after 23 years, signaling strong financial health and operational momentum.